ADVERSE REACTIONS
The data described below reflect exposure to SUTENT in 660 patients who participated in the double-blind treatment phase of a placebo-controlled trial (n=202) for the treatment of GIST [see Clinical Studies], an active-controlled trial (n=375) for the treatment of RCC [see Clinical Studies] or a placebo-controlled trial (n=83) for the treatment of pNET [see Clinical Studies]. The GIST and RCC patients received a starting oral dose of 50 mg daily on Schedule 4/2 in repeated cycles, and the pNET patients received a starting oral dose of 37.5 mg daily without scheduled off-treatment periods.
The most common adverse reactions (≥20%) in patients with GIST, RCC or pNET are fatigue, asthenia, fever, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspepsia, abdominal pain, constipation, hypertension, peripheral edema, rash, hand-foot syndrome, skin discoloration, dry skin, hair color changes, altered taste, headache, back pain, arthralgia, extremity pain, cough, dyspnea, anorexia, and bleeding. The potentially serious adverse reactions of hepatotoxicity, left ventricular dysfunction, QT interval prolongation, hemorrhage, hypertension, thyroid dysfunction, and adrenal function are discussed in
Warnings and Precautions (5)
. Other adverse reactions occurring in GIST, RCC and pNET studies are described below.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in GIST Study A
Median duration of blinded study treatment was two cycles for patients on SUTENT (mean 3.0, range 1–9) and one cycle (mean 1.8, range 1–6) for patients on placebo at the time of the interim analysis. Dose reductions occurred in 23 patients (11%) on SUTENT and none on placebo. Dose interruptions occurred in 59 patients (29%) on SUTENT and 31 patients (30%) on placebo. The rates of treatment-emergent, non-fatal adverse reactions resulting in permanent discontinuation were 7% and 6% in the SUTENT and placebo groups, respectively.
Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 56% versus 51% of patients on SUTENT versus placebo, respectively, in the double-blind treatment phase of the trial. Table 1 compares the incidence of common (≥10%) treatment-emergent adverse reactions for patients receiving SUTENT and reported more commonly in patients receiving SUTENT than in patients receiving placebo.
Table 1. Adverse Reactions Reported in Study A in at Least 10% of GIST Patients who Received SUTENT in the Double-Blind Treatment Phase and More Commonly Than in Patients Given Placebo
Adverse Reaction, n (%) |
GIST |
SUTENT (n=202) |
Placebo (n=102) |
All Grades |
Grade 3/4 |
All Grades |
Grade 3/4 |
Any
|
| 114 |
| 52 (51) |
Gastrointestinal
|
|
|
|
|
Diarrhea |
81 (40) |
9 (4) |
27 (27) |
0 (0) |
Mucositis/stomatitis |
58 (29) |
2 (1) |
18 (18) |
2 (2) |
Constipation |
41 (20) |
0 (0) |
14 (14) |
2 (2) |
Cardiac
|
|
|
|
|
Hypertension |
31 (15) |
9 (4) |
11 (11) |
0 (0) |
Dermatology
|
|
|
|
|
Skin discoloration |
61 (30) |
0 (0) |
23 (23) |
0 (0) |
Rash |
28 (14) |
2 (1) |
9 (9) |
0 (0) |
Hand-foot syndrome |
28 (14) |
9 (4) |
10 (10) |
3 (3) |
Neurology
|
|
|
|
|
Altered taste |
42 (21) |
0 (0) |
12 (12) |
0 (0) |
Musculoskeletal
|
|
|
|
|
Myalgia/limb pain |
28 (14) |
1 (1) |
9 (9) |
1 (1) |
Metabolism/Nutrition
|
|
|
|
|
Anorexia
|
67 (33) |
1 (1) |
30 (29) |
5 (5) |
Asthenia |
45 (22) |
10 (5) |
11 (11) |
3 (3) |
In the double-blind treatment phase of GIST Study A, oral pain other than mucositis/stomatitis occurred in 12 patients (6%) on SUTENT versus 3 (3%) on placebo. Hair color changes occurred in 15 patients (7%) on SUTENT versus 4 (4%) on placebo. Alopecia was observed in 10 patients (5%) on SUTENT versus 2 (2%) on placebo.
Table 2 provides common (≥10%) treatment-emergent laboratory abnormalities.
Table 2. Laboratory Abnormalities Reported in Study A in at Least 10% of GIST Patients Who Received SUTENT or Placebo in the Double-Blind Treatment Phase
Laboratory Parameter, n (%) |
GIST |
SUTENT (n=202) |
Placebo (n=102) |
All Grades
|
Grade 3/4
|
All Grades
|
Grade 3/4
|
LVEF=Left ventricular ejection fraction |
Any
|
| 68 (34) |
| 22 (22) |
Gastrointestinal
|
|
|
|
|
AST / ALT |
78 (39) |
3 (2) |
23 (23) |
1 (1) |
Lipase |
50 (25) |
20 (10) |
17 (17) |
7 (7) |
Alkaline phosphatase |
48 (24) |
7 (4) |
21 (21) |
4 (4) |
Amylase |
35 (17) |
10 (5) |
12 (12) |
3 (3) |
Total bilirubin |
32 (16) |
2 (1) |
8 (8) |
0 (0) |
Indirect bilirubin |
20 (10) |
0 (0) |
4 (4) |
0 (0) |
Cardiac
|
|
|
|
|
Decreased LVEF |
22 (11) |
2 (1) |
3 (3) |
0 (0) |
Renal/Metabolic
|
|
|
|
|
Creatinine |
25 (12) |
1 (1) |
7 (7) |
0 (0) |
Potassium decreased |
24 (12) |
1 (1) |
4 (4) |
0 (0) |
Sodium increased |
20 (10) |
0 (0) |
4 (4) |
1 (1) |
Hematology
|
|
|
|
|
Neutrophils |
107 (53) |
20 (10) |
4 (4) |
0 (0) |
Lymphocytes |
76 (38) |
0 (0) |
16 (16) |
0 (0) |
Platelets |
76 (38) |
10 (5) |
4 (4) |
0 (0) |
Hemoglobin |
52 (26) |
6 (3) |
22 (22) |
2 (2) |
After an interim analysis, the study was unblinded, and patients on the placebo arm were given the opportunity to receive open-label SUTENT treatment [see Clinical Studies]. For 241 patients randomized to the SUTENT arm, including 139 who received SUTENT in both the double-blind and open-label treatment phases, the median duration of SUTENT treatment was 6 cycles (mean 8.5, range 1 – 44). For the 255 patients who ultimately received open-label SUTENT treatment, median duration of study treatment was 6 cycles (mean 7.8, range 1 – 37) from the time of the unblinding. A total of 118 patients (46%) required dosing interruptions, and a total of 72 patients (28%) required dose reductions. The incidence of treatment-emergent adverse reactions resulting in permanent discontinuation was 20%. The most common Grade 3 or 4 treatment-related adverse reactions experienced by patients receiving SUTENT in the open-label treatment phase were fatigue (10%), hypertension (8%), asthenia (5%), diarrhea (5%), hand-foot syndrome (5%), nausea (4%), abdominal pain (3%), anorexia (3%), mucositis (2%), vomiting (2%), and hypothyroidism (2%).
Adverse Reactions in the Treatment-Naïve RCC Study
The as-treated patient population for the treatment-naive RCC study included 735 patients, 375 randomized to SUTENT and 360 randomized to IFN-α. The median duration of treatment was 11.1 months (range: 0.4 – 46.1) for SUTENT treatment and 4.1 months (range: 0.1 – 45.6) for IFN-α treatment. Dose interruptions occurred in 202 patients (54%) on SUTENT and 141 patients (39%) on IFN-α. Dose reductions occurred in 194 patients (52%) on SUTENT and 98 patients (27%) on IFN-α. Discontinuation rates due to adverse reactions were 20% for SUTENT and 24% for IFN-α. Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 77% versus 55% of patients on SUTENT versus IFN-α, respectively.
Table 3 compares the incidence of common (≥10%) treatment-emergent adverse reactions for patients receiving SUTENT versus IFN-α.
Table 3. Adverse Reactions Reported in at Least 10% of Patients with RCC Who Received SUTENT or IFN-α
Adverse Reaction, n (%) |
Treatment-Naïve RCC |
SUTENT (n=375) |
IFN-α (n=360) |
All Grades |
Grade 3/4
|
All Grades |
Grade 3/4
|
Any
|
372 (99) |
290 (77) |
355 (99) |
197 (55) |
Constitutional
|
|
|
|
|
Fatigue |
233 (62) |
55 (15) |
202 (56) |
54 (15) |
Asthenia |
96 (26) |
42 (11) |
81 (22) |
21 (6) |
Fever |
84 (22) |
3 (1) |
134 (37) |
1 (<1) |
Weight decreased |
60 (16) |
1 (<1) |
60 (17) |
3 (1) |
Chills |
53 (14) |
3 (1) |
111 (31) |
0 (0) |
Chest Pain |
50 (13) |
7 (2) |
24 (7) |
3 (1) |
Influenza like illness |
18 (5) |
0 (0) |
54 (15) |
1 (<1) |
Gastrointestinal
|
|
|
|
|
Diarrhea |
246 (66) |
37 (10) |
76 (21) |
1 (<1) |
Nausea |
216 (58) |
21 (6) |
147 (41) |
6 (2) |
Mucositis/stomatitis |
178 (47) |
13 (3) |
19 (5) |
2 (<1) |
Vomiting |
148 (39) |
19 (5) |
62 (17) |
4 (1) |
Dyspepsia |
128 (34) |
8 (2) |
16 (4) |
0 (0) |
Abdominal pain
|
113 (30) |
20 (5) |
42 (12) |
5 (1) |
Constipation |
85 (23) |
4 (1) |
49 (14) |
1 (<1) |
Dry mouth |
50 (13) |
0 (0) |
27 (7) |
1 (<1) |
GERD/reflux esophagitis |
47 (12) |
1 (<1) |
3 (1) |
0(0) |
Flatulence |
52 (14) |
0 (0) |
8 (2) |
0 (0) |
Oral pain |
54 (14) |
2 (<1) |
2 (1) |
0 (0) |
Glossodynia |
40 (11) |
0 (0) |
2 (1) |
0 (0) |
Hemorrhoids |
38 (10) |
0 (0) |
6 (2) |
0 (0) |
Cardiac
|
|
|
|
|
Hypertension |
127 (34) |
50 (13) |
13 (4) |
1 (<1) |
Edema, peripheral |
91 (24) |
7 (2) |
17 (5) |
2 (1) |
Ejection fraction decreased |
61 (16) |
10 (3) |
19 (5) |
6 (2) |
Dermatology
|
|
|
|
|
Rash |
109 (29) |
6 (2) |
39 (11) |
1 (<1) |
Hand-foot syndrome |
108 (29) |
32 (8) |
3 (1) |
0 (0) |
Skin discoloration/ yellow skin |
94 (25) |
1 (<1) |
0 (0) |
0 (0) |
Dry skin |
85 (23) |
1 (<1) |
26 (7) |
0 (0) |
Hair color changes |
75 (20) |
0 (0) |
1 (<1) |
0 (0) |
Alopecia |
51 (14) |
0 (0) |
34 (9) |
0 (0) |
Erythema |
46 (12) |
2 (<1) |
5 (1) |
0 (0) |
Pruritus |
44 (12) |
1 (<1) |
24 (7) |
1 (<1) |
Neurology
|
|
|
|
|
Altered taste
|
178 (47) |
1 (<1) |
54 (15) |
0 (0) |
Headache |
86 (23) |
4 (1) |
69 (19) |
0 (0) |
Dizziness |
43 (11) |
2 (<1) |
50 (14) |
2 (1) |
Musculoskeletal
|
|
|
|
|
Back pain |
105 (28) |
19 (5) |
52 (14) |
7 (2) |
Arthralgia |
111 (30) |
10 (3) |
69 (19) |
4 (1) |
Pain in extremity/ limb discomfort |
150 (40) |
19 (5) |
107 (30) |
7 (2) |
Endocrine
|
|
|
|
|
Hypothyroidism |
61 (16) |
6 (2) |
3 (1) |
0 (0) |
Respiratory
|
|
|
|
|
Cough |
100 (27) |
3 (1) |
51 (14) |
1 (<1) |
Dyspnea |
99 (26) |
24 (6) |
71 (20) |
15 (4) |
Nasopharyngitis |
54 (14) |
0 (0) |
8 (2) |
0 (0) |
Oropharyngeal Pain |
51 (14) |
2 (<1) |
9 (2) |
0 (0) |
Upper respiratory tract infection |
43 (11) |
2 (<1) |
9 (2) |
0 (0) |
Metabolism/Nutrition
|
|
|
|
|
Anorexia
|
182 (48) |
11 (3) |
153 (42) |
7 (2) |
Hemorrhage/Bleeding
|
|
|
|
|
Bleeding, all sites |
140 (37) |
16 (4)
|
35 (10) |
3 (1) |
Psychiatric
|
|
|
|
|
Insomnia |
57 (15) |
3 (<1) |
37 (10) |
0 (0) |
Depression
|
40 (11) |
0 (0) |
51 (14) |
5 (1) |
Treatment-emergent Grade 3/4 laboratory abnormalities are presented in Table 4.
Table 4. Laboratory Abnormalities Reported in at Least 10% of Treatment-Naïve RCC Patients Who Received SUTENT or IFN-α
Laboratory Parameter, n (%) |
Treatment-Naïve RCC |
SUTENT (n=375) |
IFN-α (n=360) |
All Grades
|
Grade 3/4
|
All Grades
|
Grade 3/4
|
Gastrointestinal
|
|
|
|
|
AST |
211 (56) |
6 (2) |
136 (38) |
8 (2) |
ALT |
192 (51) |
10 (3) |
144 (40) |
9 (2) |
Lipase |
211 (56) |
69 (18) |
165 (46) |
29 (8) |
Alkaline phosphatase |
171 (46) |
7 (2) |
132 (37) |
6 (2) |
Amylase |
130 (35) |
22 (6) |
114 (32) |
12 (3) |
Total bilirubin |
75 (20) |
3 (1) |
8 (2) |
0 (0) |
Indirect bilirubin |
49 (13) |
4 (1) |
3 (1) |
0 (0) |
Renal/Metabolic
|
|
|
|
|
Creatinine |
262 (70) |
2 (<1) |
183 (51) |
1 (<1) |
Creatine kinase |
183 (49) |
9 (2) |
40 (11) |
4 (1) |
Uric acid |
173 (46) |
54 (14) |
119 (33) |
29 (8) |
Calcium decreased |
156 (42) |
4 (1) |
145 (40) |
4 (1) |
Phosphorus |
116 (31) |
22 (6) |
87 (24) |
23 (6) |
Albumin |
106 (28) |
4 (1) |
72 (20) |
0 (0) |
Glucose increased |
86 (23) |
21 (6) |
55 (15) |
22 (6) |
Sodium decreased |
75 (20) |
31 (8) |
55 (15) |
13 (4) |
Glucose decreased |
65 (17) |
0 (0) |
43 (12) |
1 (<1) |
Potassium increased |
61 (16) |
13 (3) |
61 (17) |
15 (4) |
Calcium increased |
50 (13) |
2 (<1) |
35 (10) |
5 (1) |
Potassium decreased |
49 (13) |
3 (1) |
7 (2) |
1 (<1) |
Sodium increased |
48 (13) |
0 (0) |
38 (10) |
0 (0) |
Hematology
|
|
|
|
|
Neutrophils |
289 (77) |
65 (17) |
178 (49) |
31 (9) |
Hemoglobin |
298 (79) |
29 (8) |
250 (69) |
18 (5) |
Platelets |
255 (68) |
35 (9) |
85 (24) |
2 (1) |
Lymphocytes |
256 (68) |
66 (18) |
245 (68) |
93 (26) |
Leukocytes |
293 (78) |
29 (8) |
202 (56) |
8 (2) |
Adverse Reactions in the Phase 3 pNET Study
The median number of days on treatment was 139 days (range 13–532 days) for patients on SUTENT and 113 days (range 1–614 days) for patients on placebo. Nineteen patients (23%) on SUTENT and 4 patients (5%) on placebo were on study for >1 year. Dose interruptions occurred in 25 patients (30%) on SUTENT and 10 patients (12%) on placebo. Dose reductions occurred in 26 patients (31%) on SUTENT and 9 patients (11%) on placebo. Discontinuation rates due to adverse reactions were 22% for SUTENT and 17% for placebo.
Most treatment-emergent adverse reactions in both study arms were Grade 1 or 2 in severity. Grade 3 or 4 treatment-emergent adverse reactions were reported in 54% versus 50% of patients on SUTENT versus placebo, respectively. Table 5 compares the incidence of common (≥10%) treatment-emergent adverse reactions for patients receiving SUTENT and reported more commonly in patients receiving SUTENT than in patients receiving placebo.
Table 5. Adverse Reactions Reported in the Phase 3 pNET Study in at Least 10% of Patients who Received SUTENT and More Commonly Than in Patients Given Placebo
Adverse Reaction, n (%) |
pNET |
SUTENT (n=83) |
Placebo (n=82) |
All Grades |
Grade 3/4
|
All Grades |
Grade 3/4 |
Any
|
82 (99) |
45 (54) |
78 (95) |
41 (50) |
Constitutional
|
|
|
|
|
Asthenia |
28 (34) |
4 (5) |
22 (27) |
3 (4) |
Fatigue |
27 (33) |
4 (5) |
22 (27) |
7 (9) |
Weight decreased |
13 (16) |
1(1) |
9 (11) |
0 (0) |
Gastrointestinal
|
|
|
|
|
Diarrhea |
49 (59) |
4 (5) |
32 (39) |
2 (2) |
Stomatitis/oral Syndromes
|
40 (48) |
5 (6) |
15 (18) |
0 (0) |
Nausea |
37 (45) |
1 (1) |
24 (29) |
1 (1) |
Abdominal pain
|
32 (39) |
4 (5) |
28 (34) |
8 (10) |
Vomiting |
28 (34) |
0 (0) |
25 (31) |
2 (2) |
Dyspepsia |
12 (15) |
0 (0) |
5 (6) |
0 (0) |
Cardiac
|
|
|
|
|
Hypertension |
22 (27) |
8 (10) |
4 (5) |
1 (1) |
Dermatology
|
|
|
|
|
Hair color changes |
24 (29) |
1 (1) |
1 (1) |
0 (0) |
Hand-foot syndrome |
19 (23) |
5 (6) |
2 (2) |
0 (0) |
Rash |
15 (18) |
0 (0) |
4 (5) |
0 (0) |
Dry skin |
12 (15) |
0 (0) |
9 (11) |
0 (0) |
Neurology
|
|
|
|
|
Dysgeusia |
17 (21) |
0 (0) |
4 (5) |
0 (0) |
Headache |
15 (18) |
0 (0) |
11 (13) |
1 (1) |
Musculoskeletal
|
|
|
|
|
Arthralgia |
12 (15) |
0 (0) |
5 (6) |
0 (0) |
Psychiatric
|
|
|
|
|
Insomnia |
15 (18) |
0 (0) |
10 (12) |
0 (0) |
Hemorrhage/Bleeding
|
|
|
|
|
Bleeding events
|
18 (22) |
0 (0) |
8 (10) |
3 (4) |
Epistaxis |
17 (21) |
1 (1) |
4 (5) |
0 (0) |
Table 6 provides common (≥10%) treatment-emergent laboratory abnormalities.
Table 6. Laboratory Abnormalities Reported in the Phase 3 pNET Study in at Least 10% of Patients Who Received SUTENT
Laboratory Parameter, n (%) |
pNET |
SUTENT |
Placebo |
N |
All Grades
|
Grade 3/4
|
N |
All Grades
|
Grade 3/4
|
Gastrointestinal
|
|
|
|
|
|
|
AST increased |
82 |
59 (72) |
4 (5) |
80 |
56 (70) |
2 (3) |
ALT increased |
82 |
50 (61) |
3 (4) |
80 |
44 (55) |
2 (3) |
Alkaline phosphatase increased |
82 |
52 (63) |
8 (10) |
80 |
56 (70) |
9 (11) |
Total bilirubin increased |
82 |
30 (37) |
1 (1) |
80 |
22 (28) |
3 (4) |
Amylase increased |
74 |
15 (20) |
3 (4) |
74 |
7 (10) |
1 (1) |
Lipase increased |
75 |
13 (17) |
4 (5) |
72 |
8 (11) |
3 (4) |
Renal/Metabolic
|
|
|
|
|
|
|
Glucose increased |
82 |
58 (71) |
10 (12) |
80 |
62 (78) |
14 (18) |
Albumin decreased |
81 |
33 (41) |
1 (1) |
79 |
29 (37) |
1 (1) |
Phosphorus decreased |
81 |
29 (36) |
6 (7) |
77 |
17 (22) |
4 (5) |
Calcium decreased |
82 |
28 (34) |
0 (0) |
80 |
15 (19) |
0 (0) |
Sodium decreased |
82 |
24 (29) |
2 (2) |
80 |
27 (34) |
2 (3) |
Creatinine increased |
82 |
22 (27) |
4 (5) |
80 |
22 (28) |
4 (5) |
Glucose decreased |
82 |
18 (22) |
2 (2) |
80 |
12 (15) |
3 (4) |
Potassium decreased |
82 |
17 (21) |
3 (4) |
80 |
11 (14) |
0 (0) |
Magnesium decreased |
52 |
10 (19) |
0 (0) |
39 |
4 (10) |
0 (0) |
Potassium increased |
82 |
15 (18) |
1 (1) |
80 |
9 (11) |
1 (1) |
Hematology
|
|
|
|
|
|
|
Neutrophils decreased |
82 |
58 (71) |
13 (16) |
80 |
13 (16) |
0 (0) |
Hemoglobin decreased |
82 |
53 (65) |
0 (0) |
80 |
44 (55) |
1 (1) |
Platelets decreased |
82 |
49 (60) |
4 (5) |
80 |
12 (15) |
0 (0) |
Lymphocytes decreased |
82 |
46 (56) |
6 (7) |
80 |
28 (35) |
3 (4) |
Venous Thromboembolic Events
Seven patients (3%) on SUTENT and none on placebo in the double-blind treatment phase of GIST Study A experienced venous thromboembolic events; five of the seven were Grade 3 deep venous thrombosis (DVT), and two were Grade 1 or 2. Four of these seven GIST patients discontinued treatment following first observation of DVT.
Thirteen (3%) patients receiving SUTENT for treatment-naïve RCC had venous thromboembolic events reported. Seven (2%) of these patients had pulmonary embolism, one was Grade 2 and six were Grade 4, and six (2%) patients had DVT, including three Grade 3. One patient was permanently withdrawn from SUTENT due to pulmonary embolism; dose interruption occurred in two patients with pulmonary embolism and one with DVT. In treatment-naïve RCC patients receiving IFN-α, six (2%) venous thromboembolic events occurred; one patient (<1%) experienced a Grade 3 DVT and five patients (1%) had pulmonary embolism, all Grade 4. One patient (1%) receiving SUTENT for pNET had a venous thromboembolic event reported compared to 5 patients (6%) receiving placebo. The SUTENT patient had Grade 2 thrombosis. Two placebo patients had DVT, one was Grade 3, two placebo patients had pulmonary embolism, one was Grade 3 and one was Grade 4, and one placebo patient had Grade 3 jugular thrombosis.
Reversible Posterior Leukoencephalopathy Syndrome
There have been reports (<1%), some fatal, of subjects presenting with seizures and radiological evidence of reversible posterior leukoencephalopathy syndrome (RPLS). Patients with seizures and signs/symptoms consistent with RPLS, such as hypertension, headache, decreased alertness, altered mental functioning, and visual loss, including cortical blindness should be controlled with medical management including control of hypertension. Temporary suspension of SUTENT is recommended; following resolution, treatment may be resumed at the discretion of the treating physician.
Pancreatic and Hepatic Function
If symptoms of pancreatitis or hepatic failure are present, patients should have SUTENT discontinued. Pancreatitis was observed in 5 (1%) patients receiving SUTENT for treatment-naïve RCC compared to 1 (<1%) patient receiving IFN-α. Pancreatitis was observed in 1 (1%) patient receiving SUTENT for pNET and 1 (1%) patient receiving placebo. Hepatotoxicity was observed in patients receiving SUTENT [See Boxed Warning and Warnings and Precautions].
Post-marketing Experience
The following adverse reactions have been identified during post-approval use of SUTENT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders: thrombotic microangiopathy; hemorrhage associated with thrombocytopenia. Suspension of SUTENT is recommended; following resolution, treatment may be resumed at the discretion of the treating physician.
Gastrointestinal disorders: esophagitis
Hepatobiliary disorders: cholecystitis, particularly acalculous cholecystitis.
Immune system disorders: hypersensitivity reactions, including angioedema.
Infections and infestations: serious infection (with or without neutropenia). The infections most commonly observed with sunitinib treatment include respiratory, urinary tract, skin infections, sepsis/septic shock.
Musculoskeletal and connective tissue disorders: fistula formation, sometimes associated with tumor necrosis and/or regression; myopathy and/or rhabdomyolysis with or without acute renal failure. Patients with signs or symptoms of muscle toxicity should be managed as per standard medical practice.
Renal and urinary disorders: renal impairment and/or failure.
Respiratory disorders: pulmonary embolism.
Skin and subcutaneous tissue disorders: pyoderma gangrenosum, including positive dechallenges.
Vascular disorders: arterial thromboembolic events. The most frequent events included cerebrovascular accident, transient ischemic attack and cerebral infarction.
|